NYSE:BHVN Biohaven Pharmaceutical Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biohaven Pharmaceutical Holding Co Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $62.69 +0.44 (+0.71 %) (As of 09/28/2020 12:18 AM ET) Add Compare Share Today's Range$60.85Now: $62.69▼$63.5650-Day Range$59.04MA: $62.17▼$67.6552-Week Range$26.56Now: $62.69▼$78.75Volume588,900 shsAverage Volume834,423 shsMarket Capitalization$3.74 billionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is headquartered in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingBiohaven Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.60, Biohaven Pharmaceutical has a forecasted upside of 25.4% from its current price of $62.69.Amount of Analyst CoverageBiohaven Pharmaceutical has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesBiohaven Pharmaceutical has received 310 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiohaven Pharmaceutical has received 347 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiohaven Pharmaceutical has received 52.82% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote “Outperform” if you believe BHVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiohaven Pharmaceutical does not currently pay a dividend.Dividend GrowthBiohaven Pharmaceutical does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biohaven Pharmaceutical insiders have sold 1,280.41% more of their company's stock than they have bought. Specifically, they have bought $590,830.00 in company stock and sold $8,155,901.00 in company stock.Percentage Held by InsidersOnly 19.10% of the stock of Biohaven Pharmaceutical is held by insiders.Percentage Held by Institutions98.73% of the stock of Biohaven Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biohaven Pharmaceutical are expected to grow in the coming year, from ($11.95) to ($8.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven Pharmaceutical is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven Pharmaceutical is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CUSIPN/A CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410Debt Debt-to-Equity RatioN/A Current Ratio2.18 Quick Ratio2.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-447.79Profitability EPS (Most Recent Fiscal Year)($10.91) Net Income$-528,800,000.00 Net MarginsN/A Return on Equity-1,091.41% Return on Assets-124.20%Miscellaneous Employees63 Outstanding Shares59,686,000Market Cap$3.74 billion Next Earnings Date11/6/2020 (Estimated) OptionableOptionable $62.69 +0.44 (+0.71 %) (As of 09/28/2020 12:18 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BHVN News and Ratings via Email Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions How has Biohaven Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)? Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BHVN stock has increased by 58.9% and is now trading at $62.69. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Biohaven Pharmaceutical? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical. When is Biohaven Pharmaceutical's next earnings date? Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020. View our earnings forecast for Biohaven Pharmaceutical. How were Biohaven Pharmaceutical's earnings last quarter? Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings results on Monday, August, 10th. The company reported ($2.55) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($2.78) by $0.23. The firm earned $9.70 million during the quarter, compared to the consensus estimate of $7.43 million. During the same quarter last year, the business posted ($2.35) earnings per share. View Biohaven Pharmaceutical's earnings history. What price target have analysts set for BHVN? 11 Wall Street analysts have issued 1-year price objectives for Biohaven Pharmaceutical's stock. Their forecasts range from $41.00 to $109.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $78.60 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View analysts' price targets for Biohaven Pharmaceutical. Who are some of Biohaven Pharmaceutical's key competitors? Some companies that are related to Biohaven Pharmaceutical include Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Ascendis Pharma A/S (ASND), CureVac B.V. (CVAC), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Mirati Therapeutics (MRTX) and Myokardia (MYOK). View all competitors. What other stocks do shareholders of Biohaven Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT). Who are Biohaven Pharmaceutical's key executives? Biohaven Pharmaceutical's management team includes the following people: Dr. Vladimir Coric, CEO & Director (Age 48)Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 55)Dr. Charles Conway, Chief Scientific Officer (Age 57)Mr. Clifford Bechtold, Chief Operating OfficerMr. Matthew DeLawder, Director of Accounting When did Biohaven Pharmaceutical IPO? (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. What is Biohaven Pharmaceutical's stock symbol? Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN." Who are Biohaven Pharmaceutical's major shareholders? Biohaven Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marshall Wace LLP (4.27%), Stifel Financial Corp (4.17%), Vanguard Group Inc. (2.52%), FMR LLC (2.27%), Avidity Partners Management LP (1.85%) and Great Point Partners LLC (1.41%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical. Which major investors are selling Biohaven Pharmaceutical stock? BHVN stock was sold by a variety of institutional investors in the last quarter, including Holocene Advisors LP, Great Point Partners LLC, Bluefin Trading LLC, Stifel Financial Corp, Cormorant Asset Management LP, Barclays PLC, C WorldWide Group Holding A S, and Nicholas Investment Partners LP. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, and Robert Berman. View insider buying and selling activity for Biohaven Pharmaceutical. Which major investors are buying Biohaven Pharmaceutical stock? BHVN stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, FMR LLC, Columbus Circle Investors, Nuveen Asset Management LLC, Opaleye Management Inc., Vanguard Group Inc., Federated Hermes Inc., and Bank of New York Mellon Corp. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical. How do I buy shares of Biohaven Pharmaceutical? Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biohaven Pharmaceutical's stock price today? One share of BHVN stock can currently be purchased for approximately $62.69. How big of a company is Biohaven Pharmaceutical? Biohaven Pharmaceutical has a market capitalization of $3.74 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe. What is Biohaven Pharmaceutical's official website? The official website for Biohaven Pharmaceutical is www.biohavenpharma.com. How can I contact Biohaven Pharmaceutical? Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410. This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
